Loading…
Based on limited metadata, this Warning Letter issued to RxCash.Biz on May 29, 2018 involves a company in the "Other" product category, though the specific nature of the violations cannot be determined as the subject line is unavailable. Without access to the full letter text or identification of the issuing FDA office, the exact regulatory scope and compliance issues remain unclear. Additional documentation would be needed to provide specific details about the violations cited.